Why the Immutep (ASX:IMM) share price is sinking 16% today

This biotech has started the week deep in the red…

| More on:
An ASX investor looks devastated as he watches his computer screen, indicating bad news

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Immutep Ltd (ASX: IMM) share price has returned from its trading halt and is sinking lower on Monday morning.

At the time of writing, the biotechnology company's shares are down 16% to 51.5 cents.

Despite this decline, the Immutep share price is still up 22% since the start of the year.

Why is the Immutep share price sinking today?

The catalyst for the weakness in the Immutep share price this morning has been news that the company has secured commitments for a $60 million two-tranche institutional placement.

According to the release, the placement was undertaken at an issue price of 52 cents per share, representing a 15.5% discount to its last close price. It was supported by multiple institutional investors in Australia and offshore.

Immutep will now seek to raise a further $5 million via a share purchase plan at the same price.

Why is Immutep raising funds?

Immutep intends to use the proceeds received from the placement to fund an expanded clinical program.

This includes a new Phase III registration trial for metastatic breast cancer and a new Phase II trial for a triple combination therapy with efti, anti-PD-1 therapy, and chemotherapy.

Immutep CEO, Marc Voigt, said: "Never has there been a more exciting time to be the leading LAG-3 biotech, following the recent industry validation of this promising new immune checkpoint. Efti has continued to report compelling results from multiple clinical trials over the last year, including from key patient subgroups in our AIPAC study. Efti will be tested in different late-stage randomised settings which is a key step towards potential commercialisation."

"We are very encouraged to have received such strong support from multiple existing and new institutional investors for this financing. The funds will be used to expand our efti clinical development portfolio into late-stage settings, and significantly strengthening our strategic and business development options. They will also support the manufacturing process to reach commercial status as we advance towards registration," he added.

James Mickleboro does not own any shares mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Fallers

Person with thumbs down and a red sad face poster covering the face.
Share Fallers

Why Imricor, Ora Banda, Ventia, and Vulcan shares are dropping today

These shares are ending the week in the red. But why?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why CSL, Imricor, Jumbo, and Netwealth shares are falling today

These shares are under pressure on Thursday. But why?

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Share Fallers

Guess which ASX 200 stock is crashing 42% on big news

Big bad news is weighing heavily on this stock today.

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Share Fallers

Why Beetaloo, Botanix, Cobram Estate, and Origin Energy shares are falling today

These shares are having a poor session on Tuesday. But why?

Read more »

Bored man sitting at his desk with his laptop.
Share Fallers

Why Antipa Minerals, Northern Star, Pilbara Minerals, and Synlait Milk shares are falling today

These shares are starting the week in the red. But why?

Read more »

a man weraing a suit sits nervously at his laptop computer biting into his clenched hand with nerves, and perhaps fear.
Share Fallers

Why Evolution Mining, G8 Education, Lottery Corp, and Lynas shares are tumbling today

These shares are ending the week in the red. But why?

Read more »

Two men in hard hats and high visibility jackets look together at a laptop screen at a mine site.
Gold

Down 50% in a year, time to pounce on this beaten-down ASX 200 gold stock?

A leading expert offers his verdict on this beaten-down ASX 200 gold miner.

Read more »

Three guys in shirts and ties give the thumbs down.
Share Fallers

Why CBA, G8 Education, JB Hi-Fi, and Vault Minerals shares are falling today

These shares are falling on Thursday. But why?

Read more »